Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsLAB -3.77%33 Equity-to-Asset is 0.86 as of Jun. 2026, which is 132% above its 10-year median of 0.37. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Fairly Valued). The stock has 5 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Standard BioTools ranks better than 85.19% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Standard BioTools's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $539.97 Mil. Standard BioTools's Total Assets for the quarter that ended in Jun. 2026 was $627.22 Mil.
Therefore, Standard BioTools's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.86.
The historical rank and industry rank for Standard BioTools's Equity-to-Asset or its related term are showing as below:
LAB'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.46 Med: 0.37 Max: 0.88
Current: 0.86
During the past 13 years, the highest Equity to Asset Ratio of Standard BioTools was 0.88. The lowest was -0.46. And the median was 0.37.
LAB's Equity-to-Asset is ranked better than 85.19% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs LAB: 0.86
Standard BioTools (NAS:LAB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Standard BioTools Equity-to-Asset Related Terms
Standard BioTools Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Standard BioTools's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Standard BioTools's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (LAB) has a Equity-to-Asset of 0.86 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Standard BioTools and its competitors. This is 132% above median its historical median of 0.37. According to the industry distribution chart, Standard BioTools ranks #126 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 14.8%.
Is Standard BioTools' Equity-to-Asset too high?
Standard BioTools' current Equity-to-Asset of 0.86 is 132% above median its 10-year median of 0.37. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Standard BioTools' value of 0.86 is 34.4% above this industry median. Based on the distribution chart, Standard BioTools ranks #126 out of 851 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Equity-to-Asset compare to CV and ELMD?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #126 out of 851 companies for Equity-to-Asset. This places Standard BioTools in the top 15% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Standard BioTools' value of 0.86 is 34.4% above this benchmark. While the company's 10-year median is 0.37 vs. the industry median of 0.64, Standard BioTools has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current Equity-to-Asset of 0.86 is 34.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current Equity-to-Asset is 0.86, which is 132% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Fairly Valued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 9% below its estimated fair value. The current Equity-to-Asset is 0.86, which is 132% above median its 10-year median of 0.37 and 34.4% above the Medical Devices & Instruments industry median of 0.64. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Standard BioTools (LAB), the current Equity-to-Asset is 0.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued.
The current stock price of $0.65 is trading 9% below its estimated GF Value™ of $0.71.
GuruFocus considers Standard BioTools to be Fairly Valued.
Key valuation signals for LAB:
Equity-to-Asset: 0.86 (132% above median its 10-year median of 0.37)
GF Value™: $0.71 vs. price of $0.65 (9% below fair value)
Industry Position: 34.4% above the Medical Devices & Instruments median (#126 of 851)
No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score
Get the complete analysis for LAB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LAB has been successfully added to your 
